Last Updated: October 25, 2026
A 10% cleanser, an 8% leave-on cream and a professional peel are not three interchangeable strengths of the same treatment. That distinction matters more than a chart calling one acid the strongest and another the gentlest.
Medical disclaimer: This guide explains research, not a personalized treatment plan or instructions for chemical peeling. Consult a qualified clinician for acne, rosacea, eczema, persistent pigmentation, pregnancy or breastfeeding, medication interactions or a history of reactions. Do not perform professional-strength or TCA peels at home.
The comparison that matters: ingredient, formula, endpoint
Tier 2 for formulation-dependent clinical effects: Stiller et al. (1996), Archives of Dermatology, studied 8% glycolic-acid and 8% L-lactic-acid creams against vehicle for 22 weeks in 74 women with photodamaged skin. At least one grade of improvement in overall facial photodamage occurred in 76%, 71% and 40%, respectively. The authors described the benefits as modest. Those results belong to the tested creams and population, not every cleanser or mask containing either acid. PMID: 8651713.
Use three questions throughout this guide: What preparation was studied? What was it compared with? What actually improved? Molecular size alone does not answer them.
Our editorial tiers are claim-specific: Tier 1 requires multiple relevant randomized human trials; Tier 2 denotes limited human clinical support; Tier 3 mainly mechanistic evidence; Tier 4 a proposed clinical benefit unconfirmed by the evidence reviewed. A review article or a familiar ingredient name does not automatically earn a Tier 1 label.
Glycolic acid: useful evidence, not automatic superiority
Tier 2 for the defined leave-on result: The Stiller trial supports modest improvement in some photodamage signs with a particular 8% glycolic-acid cream. It does not establish that glycolic acid delivers the best result for every skin concern, that smaller molecules always mean greater clinical benefit, or that a rinse-off wash reproduces a twice-daily leave-on study. Stiller et al. (1996), Archives of Dermatology, PMID: 8651713.
Tier 2 for a UV-sensitivity finding: Kornhauser et al. (2009), Journal of Dermatological Science, studied 14 participants using 10% glycolic acid, 2% salicylic acid, vehicle and untreated back-skin sites. After 3.5 weeks, glycolic acid increased sensitivity to simulated solar radiation on measured endpoints. Salicylic acid did not significantly change those endpoints. The experiment does not establish identical effects for every formula or a sunscreen effect for salicylic acid. PMID: 19411163.
What it does not establish: A glycolic cleanser is not automatically gentler than a leave-on product, and rinsing does not eliminate irritation risk. Do not infer a safe exposure time from a different product's trial.
Lactic acid: concentration and outcomes need to stay attached
Tier 2 for clinical and tissue observations: Smith (1996), Journal of the American Academy of Dermatology, compared topical 5% and 12% lactic acid used twice daily for three months. Both showed clinical and epidermal changes, but dermal changes were reported with 12%, not 5%. That is a useful warning against treating every lactic-acid concentration as biologically equivalent. It is not advice to choose the higher concentration. PMID: 8784274.
The vehicle-controlled trial of 8% L-lactic-acid cream also reported modest photodamage benefits. It did not establish universal suitability for sensitive skin or a guarantee that lactic acid is gentler than every glycolic formulation. Stiller et al. (1996), Archives of Dermatology, PMID: 8651713.
What it does not do: A hydration-related ingredient property does not establish that an exfoliating formula cannot irritate. “Lactic” is not a permission slip for daily use on an already reactive face.
Mandelic acid: a professional-peel study is not a serum trial
Tier 2 for a small comparative clinical study: Dayal et al. (2020; published online 2019), Journal of Cosmetic Dermatology, randomized 50 patients with mild-to-moderate acne to 45% mandelic-acid or 30% salicylic-acid peels over 12 weeks. Overall acne-score improvements did not differ significantly; adverse effects were fewer with mandelic acid in this study. Nonsignificance is not proof of equivalence, and this was not a test of a 10% home serum. PMID: 31553119.
Tier 4 for a universal safety ranking: This comparison cannot establish mandelic acid as the safest AHA for every darker skin tone, a guaranteed option for reactive skin, or an ingredient that never causes post-inflammatory pigmentation. Nor does the trial validate enhanced brightening from adding niacinamide. Dayal et al. (2020), Journal of Cosmetic Dermatology, PMID: 31553119.
Do not use a home patch test to clear a known allergy concern. Ask a qualified clinician about the actual formulation rather than inferring safety or allergen content from the ingredient's name or historical source.
Salicylic acid: an acne option, not the only pore treatment
Tier 2 for this clinical option: Reynolds et al. (2024), Journal of the American Academy of Dermatology, conditionally recommend salicylic acid for acne while strongly recommending other options, including topical retinoids and benzoyl peroxide. This is not support for declaring salicylic acid uniquely effective or best for every oily face. PMID: 38300170.
Liu et al. (2020), Cochrane Database of Systematic Reviews, found important uncertainty in salicylic-acid comparisons, with low- or very-low-quality evidence for many outcomes. The review spans several ingredients; its entire participant count cannot be credited to salicylic acid. PMID: 32356369.
What it does not establish: Oil-related ingredient properties do not guarantee normalized sebum production, permanent pore shrinkage or a fixed blackhead-clearance date. Read our salicylic-acid blackhead evidence and application guide for the treatment-specific distinctions.
PHAs: promising tolerability is not zero risk
Tier 2 for a regimen-specific comparison: Edison et al. (2004), Cutis, compared gluconolactone-containing and glycolic-acid-containing regimens over 12 weeks. Both regimens showed improvements on assessed photoaging measures, and the PHA regimen was better tolerated on irritation assessments. The authors had a manufacturer affiliation, and the comparison concerned whole regimens rather than every PHA and AHA product. PMID: 15002657.
What it does not establish: This is not evidence that any PHA can be used daily around the eyes, on an eczema flare or immediately after a procedure. It does not make “under-exfoliation” the only meaningful risk. Better tolerability in a study does not remove the need for product-specific directions or individualized care.
TCA: a professional decision, not the next home-care level
Tier 2 for the clinical literature summarized here, not a blanket Tier 1 endorsement: Soleymani et al. (2018), Journal of Clinical and Aesthetic Dermatology, review chemical peeling as a controlled tissue-injury procedure whose depth and outcomes depend on the agent and technique. Their professional treatment review is not a validation of an at-home TCA schedule. PMID: 30214663.
The FDA's July 2024 chemical-peel safety warning describes risks including severe burns, infection, pigment changes and scarring, and advises appropriate professional supervision. Concentration, number of applications and contact time all influence injury depth.
We have removed the former reassurance that low-concentration home TCA peels are generally safe and the suggested four-to-six-week interval. Do not copy professional concentrations, neutralization steps, layering techniques or downtime expectations from a reference article. A trained provider should assess whether a peel is appropriate at all.
A practical decision framework before you add an acid
- Name one goal. Acne, roughness and persistent pigmentation are different questions. Do not select by an ingredient popularity ranking.
- Separate formats. Identify whether the evidence concerns a leave-on cream, a rinse-off cosmetic, a complete regimen or a professional procedure.
- Read your product's directions. Do not import exposure time, frequency, concentration or application area from another formula.
- Avoid an escalation ladder. You do not have to progress from PHA to lactic to glycolic to TCA. Stronger treatment is not a skincare achievement.
- Keep changes interpretable. A single change makes it easier to discuss benefit or irritation with a clinician than adding three exfoliants at once. This is a practical monitoring suggestion, not a validated universal schedule.
- Respect reactions. Stop and seek appropriate advice for persistent burning, swelling, a worsening rash or a suspected burn. Do not assume visible peeling means a better result.
- Plan sun protection separately. Follow complete-formulation warnings and professional aftercare. An acid or a moisturizer is not a substitute for sunscreen.
Optional cosmetic care, not a mandatory exfoliation stack
The Pre- & Probiotic Nourishing Moisturizer is catalog-listed as fragrance-free and contains hyaluronic acid. It is included as optional moisturizer shopping context, not as a tested companion to every acid or proof of barrier repair after a peel. Its name does not establish a clinical microbiome effect.
We have removed the previous multi-acid shopping routine rather than presenting different ingredient studies as evidence for layering finished retail products. No purchase is needed to understand the evidence map above.
Commercial disclosure: Veracil sells the moisturizer below. It was not the product studied in the cited acid trials and is not endorsed here for use on a chemical burn, immediately after a procedure or as a treatment enhancer.
Related reading and the limits of an ingredient encyclopedia
For a narrower comparison, read glycolic acid versus lactic acid. For ingredients whose brightening claims should not be confused with exfoliation, see the brightening-ingredient evidence guide. Neither link is an instruction to combine its ingredients with this guide's acids.
A trial in photodamaged skin cannot establish treatment of eczema. A professional acne-peel comparison cannot validate every home serum. A better-tolerated regimen cannot guarantee safety for every sensitive person. These boundaries are central to interpreting Stiller et al. (1996), Archives of Dermatology, PMID: 8651713; Dayal et al. (2020), Journal of Cosmetic Dermatology, PMID: 31553119; and Edison et al. (2004), Cutis, PMID: 15002657.
The calibrated verdict
Preliminary Confirm: Specific AHA creams, a PHA regimen and selected professional-peel approaches have supportive clinical findings, but the results must remain attached to their formulations, populations and outcomes. The named trials above do not establish a universal best acid.
Inconclusive: Molecule-size safety rankings, guaranteed sensitive-skin compatibility, automatic benefits from acid stacking and treating a rinse-off formula as equivalent to a leave-on trial. Bust: The claim that salicylic acid is the only effective acne option; the 2024 guideline recommends several established alternatives. Reynolds et al. (2024), Journal of the American Academy of Dermatology, PMID: 38300170.
Choose by the question the evidence answers, not by the strongest percentage you can buy.
The Veracil Research Team
0 comments